Preclinical Support Services

Size: px
Start display at page:

Download "Preclinical Support Services"

Transcription

1 Preclinical Support Services Expert toxicology solutions providing consultation, study design testing and site monitoring to ensure a seamless transition of projects through IND-enabling studies and into clinical trials.

2 Study Design, Consultation and Monitoring Our Services NSF s expert toxicologists provide a complete package of consultation, study design Preclinical Study Design, Support and Monitoring and site monitoring services to ensure a seamless transition of your project through Complete design and support for IND-enabling study package Site auditing and monitoring analysis as needed, to provide a comprehensive report that is directly suitable for Formulation development and analysis regulatory submission. Toxicology and pharmacokinetic reporting The Right People. The Right Solution. The First Time. Clinical and Preclinical Bioanalysis NSF Health Sciences provides expert preclinical laboratory support, consulting and Method Development and Validation Plasma, blood, serum, synovial fluid, urine and feces Tissues the required IND-enabling studies and into clinical trials. Our services also include complete toxicological risk assessment, including DEREK training to the pharmaceutical, medical device and biotechnology industries. Our scientific, technical and project management staff is committed to supporting you through the product development cycle including bioanalytical methods development, validation and sample analysis. For more information about NSF Health Sciences and our preclinical services, please contact us at or call Liver, kidney, spleen, brain, spinal cord, heart, eye, muscle, dermis Species - Non-human primate, rodent, canine, porcine, bovine and human Validation according to FDA guidance Sample Analysis Small and large molecules, oligonucleotides and aptamers Liquid-liquid extraction, solid phase extraction, protein precipitation, digestion UPLC/MS/MS, Waters UNIFI software Watson LIMS Bioanalytical Methods Development, Validation and Sample Analysis NSF provides bioanalytical methods development, validation and sample analysis in its FDA-GLP registered facility in Bristol, CT. We support all types of preclinical studies from early discovery (ADME, PK, TK) through long-term chronic in all species. In addition to the traditional matrices of blood, plasma and urine, the NSF bioanalysis group has many years of methods development experience in complex matrices such as brain, spleen, spinal cord, and vaginal tissue to name a few. Sample data is processed and reported using the Watson LIMS. All reports are delivered as ready to file documents. We also offer full API characterization as well as formulation concentration and stability analysis. In-Life Study Support NSF Health Sciences strategically partners with service providers to offer in-life studies in a variety of models. American Preclinical Services (APS), located in Coon Rapids, MN, performs ISO10993 and custom biocompatibility testing, interventional and surgical large animal research, toxicology, and pathology services. BioTox Sciences (BTS), located in San Diego, CA, provides GLP and non-glp toxicology studies including acute toxicity, subchronic toxicity, chronic toxicity, rangefinding studies, maximum tolerated dose, and safety pharmacology to investigate the effects of the test substance on vital functions including cardiovascular, respiratory, and central nervous systems.

3 Study Design, Consultation and Monitoring Our Services NSF s expert toxicologists provide a complete package of consultation, study design Preclinical Study Design, Support and Monitoring and site monitoring services to ensure a seamless transition of your project through Complete design and support for IND-enabling study package Site auditing and monitoring analysis as needed, to provide a comprehensive report that is directly suitable for Formulation development and analysis regulatory submission. Toxicology and pharmacokinetic reporting The Right People. The Right Solution. The First Time. Clinical and Preclinical Bioanalysis NSF Health Sciences provides expert preclinical laboratory support, consulting and Method Development and Validation Plasma, blood, serum, synovial fluid, urine and feces Tissues the required IND-enabling studies and into clinical trials. Our services also include complete toxicological risk assessment, including DEREK training to the pharmaceutical, medical device and biotechnology industries. Our scientific, technical and project management staff is committed to supporting you through the product development cycle including bioanalytical methods development, validation and sample analysis. For more information about NSF Health Sciences and our preclinical services, please contact us at or call Liver, kidney, spleen, brain, spinal cord, heart, eye, muscle, dermis Species - Non-human primate, rodent, canine, porcine, bovine and human Validation according to FDA guidance Sample Analysis Small and large molecules, oligonucleotides and aptamers Liquid-liquid extraction, solid phase extraction, protein precipitation, digestion UPLC/MS/MS, Waters UNIFI software Watson LIMS Bioanalytical Methods Development, Validation and Sample Analysis NSF provides bioanalytical methods development, validation and sample analysis in its FDA-GLP registered facility in Bristol, CT. We support all types of preclinical studies from early discovery (ADME, PK, TK) through long-term chronic in all species. In addition to the traditional matrices of blood, plasma and urine, the NSF bioanalysis group has many years of methods development experience in complex matrices such as brain, spleen, spinal cord, and vaginal tissue to name a few. Sample data is processed and reported using the Watson LIMS. All reports are delivered as ready to file documents. We also offer full API characterization as well as formulation concentration and stability analysis. In-Life Study Support NSF Health Sciences strategically partners with service providers to offer in-life studies in a variety of models. American Preclinical Services (APS), located in Coon Rapids, MN, performs ISO10993 and custom biocompatibility testing, interventional and surgical large animal research, toxicology, and pathology services. BioTox Sciences (BTS), located in San Diego, CA, provides GLP and non-glp toxicology studies including acute toxicity, subchronic toxicity, chronic toxicity, rangefinding studies, maximum tolerated dose, and safety pharmacology to investigate the effects of the test substance on vital functions including cardiovascular, respiratory, and central nervous systems.

4 Study Design, Consultation and Monitoring Our Services NSF s expert toxicologists provide a complete package of consultation, study design Preclinical Study Design, Support and Monitoring and site monitoring services to ensure a seamless transition of your project through Complete design and support for IND-enabling study package Site auditing and monitoring analysis as needed, to provide a comprehensive report that is directly suitable for Formulation development and analysis regulatory submission. Toxicology and pharmacokinetic reporting The Right People. The Right Solution. The First Time. Clinical and Preclinical Bioanalysis NSF Health Sciences provides expert preclinical laboratory support, consulting and Method Development and Validation Plasma, blood, serum, synovial fluid, urine and feces Tissues the required IND-enabling studies and into clinical trials. Our services also include complete toxicological risk assessment, including DEREK training to the pharmaceutical, medical device and biotechnology industries. Our scientific, technical and project management staff is committed to supporting you through the product development cycle including bioanalytical methods development, validation and sample analysis. For more information about NSF Health Sciences and our preclinical services, please contact us at or call Liver, kidney, spleen, brain, spinal cord, heart, eye, muscle, dermis Species - Non-human primate, rodent, canine, porcine, bovine and human Validation according to FDA guidance Sample Analysis Small and large molecules, oligonucleotides and aptamers Liquid-liquid extraction, solid phase extraction, protein precipitation, digestion UPLC/MS/MS, Waters UNIFI software Watson LIMS Bioanalytical Methods Development, Validation and Sample Analysis NSF provides bioanalytical methods development, validation and sample analysis in its FDA-GLP registered facility in Bristol, CT. We support all types of preclinical studies from early discovery (ADME, PK, TK) through long-term chronic in all species. In addition to the traditional matrices of blood, plasma and urine, the NSF bioanalysis group has many years of methods development experience in complex matrices such as brain, spleen, spinal cord, and vaginal tissue to name a few. Sample data is processed and reported using the Watson LIMS. All reports are delivered as ready to file documents. We also offer full API characterization as well as formulation concentration and stability analysis. In-Life Study Support NSF Health Sciences strategically partners with service providers to offer in-life studies in a variety of models. American Preclinical Services (APS), located in Coon Rapids, MN, performs ISO10993 and custom biocompatibility testing, interventional and surgical large animal research, toxicology, and pathology services. BioTox Sciences (BTS), located in San Diego, CA, provides GLP and non-glp toxicology studies including acute toxicity, subchronic toxicity, chronic toxicity, rangefinding studies, maximum tolerated dose, and safety pharmacology to investigate the effects of the test substance on vital functions including cardiovascular, respiratory, and central nervous systems.

5 Our People James R. Scull, Ph.D. General Manager James Scull has more than 27 years of pharmaceutical development experience spanning all areas from discovery support through manufacturing. Dr. Scull s primary expertise is in the areas of applied analytical chemistry, toxicology and multi-dimensional separation science. He is also an expert in conducting extractable & leachable studies and oligonucleotide analysis. Kurt L. Moyer, Ph.D. Director of Research Kurt Moyer has more than 23 years of pharmaceutical development experience spanning all areas from discovery support to marketed products. His primary expertise is in the areas of bioanalysis, extractables and leachables, method development and validation, identification of impurities and metabolites, and GLP/ GMP compliance. He also has extensive experience with drugs for anticoagulant and cardiovascular therapies. Ulyana V. Matyugicheva, M.S. Group Leader, Bioanalysis Ulyana Matyugicheva has nearly 10 years of pharmaceutical development experience covering areas from early discovery studies to human clinical trials. Ms. Matyugicheva s primary focus is in analytical methods development in complex matrices, with an emphasis on novel extraction techniques. She also oversees development and implementation of new analytical technologies. John M. Mitchell, Ph.D. Consulting Toxicologist John Mitchell has over 20 years of experience in clinical study development and monitoring. With expertise in FDA, ICH, ISO, EMEA, Prop 65 and EPA guidelines, Dr. Mitchell provides safety evaluation and regulatory submissionadvice. He has conducted diligence of over 60 pharmaceuticals and medical device in-license opportunities.

6 Our Global Presence NSF Health Sciences Locations NORTH AMERICA > Ann Arbor, MI > Bristol, CT > Washington, DC EUROPE > Berlin, Germany > Sheffield, UK > York, UK LATIN AMERICA > Lima, Peru ASIA > Shanghai, China For more information about NSF Health Sciences preclinical support and testing services, contact call or visit LHS

Global Lab Capabilities Pharma Biotech

Global Lab Capabilities Pharma Biotech Global Lab Capabilities Pharma Biotech NSF Health Sciences global network of laboratories delivers expert solutions to pharmaceutical, biotechnology and medical device companies in the areas of analytical

More information

Clinical trials preclinical requirements. Clinical trials - legislation

Clinical trials preclinical requirements. Clinical trials - legislation Clinical trials preclinical requirements Mikael Andersson, PhD Senior Expert Medical Products Agency, Sweden Tallinn 9/10 2009 Clinical trials - legislation Directive 2001/20/EC Clinical trial directive

More information

Total Product Lifecycle Solutions from NSF Pharma Biotech. Experts in pharma training, consultancy, auditing and analytical testing.

Total Product Lifecycle Solutions from NSF Pharma Biotech. Experts in pharma training, consultancy, auditing and analytical testing. Total Product Lifecycle Solutions from NSF Pharma Biotech Experts in pharma training, consultancy, auditing and analytical testing www.nsf.org About Us NSF Pharma Biotech is a major global provider of

More information

Non-clinical development of biologics

Non-clinical development of biologics Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service

More information

Rochester BioVenture Center November 14th

Rochester BioVenture Center November 14th Rochester BioVenture Center November 14th Calvert Holdings, Inc. Established in 1996 Parent company for several subsidiaries Focus: health care services and investments Corporate HQ located in Cary, NC

More information

4.1 Objectives of Clinical Trial Assessment

4.1 Objectives of Clinical Trial Assessment L1 4.1 Objectives of Clinical Trial Assessment Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office of Clinical

More information

From The Lab To Your Medicine Cabinet:

From The Lab To Your Medicine Cabinet: From The Lab To Your Medicine Cabinet: A Pharmaceutical Drug s Journey Presented by: Dr. Steven Hansel Sr. Director; Pfizer Moderated by: Sam Gilchrist Ph.D. Candidate; UBC The Drug Development Process

More information

A FDA Perspective on Nanomedicine Current Initiatives in the US

A FDA Perspective on Nanomedicine Current Initiatives in the US A FDA Perspective on Nanomedicine Current Initiatives in the US Carlos Peña, PhD Office of the Commissioner FDA September 3, 2010 Outline Context Nanotechnology Task Force report summary Identification

More information

How to develop Antibody Drug Conjugates: Bioanalysis Contribution

How to develop Antibody Drug Conjugates: Bioanalysis Contribution How to develop Antibody Drug Conjugates: Bioanalysis Contribution Recommendations and survey results Presenter: Matt Barfield on behalf of the EBF TT43 7th Open Symposium 19 th November 2014 Barcelona

More information

exactly. The need for efficiency in developing effective new therapeutics has never been greater.

exactly. The need for efficiency in developing effective new therapeutics has never been greater. exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,

More information

NSF Dietary Supplements Complete Service Offering. Experts in supplement auditing, testing and training.

NSF Dietary Supplements Complete Service Offering. Experts in supplement auditing, testing and training. NSF Dietary Supplements Complete Service Offering Experts in supplement auditing, testing and training www.nsf.org About Us NSF International is the Public Health and Safety Organization, offering public

More information

Introducing the Pharmaceutical Consultancy, Auditing & Training Experts

Introducing the Pharmaceutical Consultancy, Auditing & Training Experts The right people. The right solution. The first time. Introducing the Pharmaceutical Consultancy, Auditing & Training Experts www.nsf.org/info/pharmabiotech Introducing the Pharmaceutical Consultancy,

More information

Guidance for Industry Safety Testing of Drug Metabolites

Guidance for Industry Safety Testing of Drug Metabolites Guidance for Industry Safety Testing of Drug Metabolites U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2008 Pharmacology

More information

SERVICES FOR. Devices and Combination Products

SERVICES FOR. Devices and Combination Products SERVICES FOR Devices and Combination Products How to Contact Us U.S. FACILITIES / CLIENT SERVICES St. Paul 2540 Executive Drive St. Paul, MN 55120 FAX 651.675.2005 Atlanta 1265 Kennestone Circle Marietta,

More information

DMPK: Experimentation & Data

DMPK: Experimentation & Data DMPK: Experimentation & Data Interpretation Mingshe Zhu, Mike S. Lee, Naidong Weng, and Mark Hayward Prerequisite: Entry-level scientists with hands on experience in LC/MS as well as advanced students

More information

PEOPLE > SCIENCE > SOLUTIONS

PEOPLE > SCIENCE > SOLUTIONS PEOPLE > SCIENCE > SOLUTIONS Our difference Our foundation Our focus ANALYTICAL CHEMISTRY & MATERIALS CHARACTERIZATION EFFICACY (Functional testing) BIOCOMPATIBILITY (in vivo & in vitro toxicology) CLINICAL

More information

Working with ICH Quality Guidelines - the Canadian Perspective

Working with ICH Quality Guidelines - the Canadian Perspective Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 23 July 1998 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL

More information

Pharmacology skills for drug discovery. Why is pharmacology important?

Pharmacology skills for drug discovery. Why is pharmacology important? skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th

More information

Drug Discovery & Development. Neal G. Simon, Ph.D. Professor Department of Biological Sciences

Drug Discovery & Development. Neal G. Simon, Ph.D. Professor Department of Biological Sciences Drug Discovery & Development Neal G. Simon, Ph.D. Professor Department of Biological Sciences Drug Discovery & Development: Bench, Bedside, & Beyond I. Background II. The R&D Landscape III. Innovation

More information

Basic Overview of Preclinical Toxicology Animal Models

Basic Overview of Preclinical Toxicology Animal Models Basic Overview of Preclinical Toxicology Animal Models Charles D. Hebert, Ph.D., D.A.B.T. December 5, 2013 Outline Background In Vitro Toxicology In Vivo Toxicology Animal Models What is Toxicology? Background

More information

Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013

Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013 Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory

More information

Overview of Drug Development: the Regulatory Process

Overview of Drug Development: the Regulatory Process Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger

More information

Session 6 Clinical Trial Assessment Phase I Clinical Trial

Session 6 Clinical Trial Assessment Phase I Clinical Trial L1 Session 6 Clinical Trial Assessment Phase I Clinical Trial Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office

More information

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5 European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS

More information

New approaches in regulatory toxicology: why we need to change. Contemporary Concepts in Toxicology Webinar Series 18 June 2015 Kathryn Chapman, PhD

New approaches in regulatory toxicology: why we need to change. Contemporary Concepts in Toxicology Webinar Series 18 June 2015 Kathryn Chapman, PhD New approaches in regulatory toxicology: why we need to change Contemporary Concepts in Toxicology Webinar Series 18 June 2015 Kathryn Chapman, PhD Background: Current and future approaches in three areas:

More information

Preclinical Development to IND: Drugs and Vaccines

Preclinical Development to IND: Drugs and Vaccines Preclinical Development to IND: Drugs and Vaccines Maralee McVean, PhD Vice President, Pharmacology and Toxicology Services PreClinical Research Services, Inc. maralee.mcvean@preclinicalresearch.com Overview

More information

The Aptuit Center for Drug Discovery & Development Verona, Italy. Uncommon Expertise. Exceptional Results.

The Aptuit Center for Drug Discovery & Development Verona, Italy. Uncommon Expertise. Exceptional Results. The Aptuit Center for Drug Discovery & Development Verona, Italy Uncommon Expertise. Exceptional Results. 2 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit in Verona: uncommon expertise,

More information

EXTRACTABLES AND LEACHABLES FOR MEDICAL DEVICES: MEETING THE 510 (k) REQUIREMENTS

EXTRACTABLES AND LEACHABLES FOR MEDICAL DEVICES: MEETING THE 510 (k) REQUIREMENTS EXTRACTABLES AND LEACHABLES FOR MEDICAL DEVICES: MEETING THE 510 (k) REQUIREMENTS BIOGRAPHICAL NOTE Kurt Moyer, Ph.D. Director of Research, NSF Pharmalytica Bristol, Connecticut, USA 06010 Tel: 1(860)

More information

Human ADME and Studies with Radiolabeled Compounds: Phase I-IIa

Human ADME and Studies with Radiolabeled Compounds: Phase I-IIa WHITE PAPER Human ADME and Studies with Radiolabeled Compounds: Phase I-IIa AD ROFFEL, PhD Director, Global Scientific Affairs PRA Health Sciences Authors: HENK POELMAN, MSc Project Manager, Laboratory

More information

Lilly Covance Strategic Alliance From Vision to Results. Adrienne Takacs, PhD Jonathan Koch, MBA

Lilly Covance Strategic Alliance From Vision to Results. Adrienne Takacs, PhD Jonathan Koch, MBA Lilly Covance Strategic Alliance From Vision to Results Adrienne Takacs, PhD Jonathan Koch, MBA Topics 1. Lilly s Challenge... a Partnership Opportunity 2. Our Landmark Agreement 3. A Local Success Story

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES

More information

Testing Services for Large Molecule Drug Development

Testing Services for Large Molecule Drug Development Testing Services for Large Molecule Drug Development Our mission is to extend our clients capabilities by combining scientific knowledge, capacity, regulatory expertise and flexibility to provide the trusted,

More information

NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS

NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS

More information

Product Development Services for Global Registration of Drugs & Biologics. 16-17 th April 2014. Contact: kevin.breesch@toxikon.be

Product Development Services for Global Registration of Drugs & Biologics. 16-17 th April 2014. Contact: kevin.breesch@toxikon.be Product Development Services for Global Registration of Drugs & Biologics 16-17 th April 2014 Contact: kevin.breesch@toxikon.be CONTENT OF PRESENTATION» History» Company Profile» Current Services» Proof-of-Concept:

More information

BIOTECHNOLOGY OPERATIONS

BIOTECHNOLOGY OPERATIONS BIOTECHNOLOGY OPERATIONS Principles and Practices Michael J. Roy TECHNISCHE INFORMATION SBIBLIOTHEK UNIVERSITATSBIBLIOTHEK HANNOVER CRC Press TaylorStFrancis Croup Boca Raton London New York CRC Press

More information

Guidance for Industry

Guidance for Industry Guidance for Industry S9 Nonclinical Evaluation for Anticancer Pharmaceuticals U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center

More information

Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials

Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials Ron Hinkel, Director Quality Systems BioReliance Inc. Patti Rossman, President Globiox Purpose Keep pace

More information

1) Aug 2005 In Vitro Chromosomal Aberration Study Cytotoxicity (File: TS39) Conclusion No cytotoxicity can be detected at concentrations up to 100%.

1) Aug 2005 In Vitro Chromosomal Aberration Study Cytotoxicity (File: TS39) Conclusion No cytotoxicity can be detected at concentrations up to 100%. Endotoxicity and Cytotoxicity Studies 1) Aug 2005 In Vitro Chromosomal Aberration Study Cytotoxicity (File: TS39) Chinese Hamster Ovary (CHO) cells were grown in monolayer with and without metabolic activation.

More information

We Know. You need to be certain. Every time. An NSF International Company

We Know. You need to be certain. Every time. An NSF International Company We Know. You need to be certain. Every time. An NSF International Company ScieNTiFic ANd TecHNicAl expertise NSF International is a global, independent public health and safety organization whose mission

More information

Lead optimization services

Lead optimization services Lead optimization services The WIL Research Company (WRC) has extensive experience in fast track tailor-made screening strategies to help you with the challenging task of selecting your best candidate

More information

Roles & Responsibilities of the Sponsor

Roles & Responsibilities of the Sponsor Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from

More information

Biological importance of metabolites. Safety and efficacy aspects

Biological importance of metabolites. Safety and efficacy aspects Biological importance of metabolites Safety and efficacy aspects Bernard Walther Technologie Servier Biological importance of metabolites Safety testing of drug metabolites Bioanalytical strategy Structural

More information

NEW CHEMICAL ENTITIES

NEW CHEMICAL ENTITIES NEW CHEMICAL ENTITIES PIONEERING PARTNER FOR PEPTIDES With more than 40 years of expertise in peptide synthesis, a track record in process development, large-scale manufacturing and outstanding product

More information

Requirements of mouse models by Pharmaceutical Industry. EFPIA opinions

Requirements of mouse models by Pharmaceutical Industry. EFPIA opinions Requirements of mouse models by Pharmaceutical Industry. EFPIA opinions INFRAFRONTIER meeting Barcelona, November 13 th 2014 Eduard Valenti ESTEVE Disclaimer Informations compiled in this presentation

More information

The Facts on Equine Drug Testing

The Facts on Equine Drug Testing The Facts on Equine Drug Testing CONTACT Travis Mays, MS Interim Section Head Analytical Chemistry, Drug Testing Laboratory Toxicology Laboratory 979.845.3414 tmays@ LIMITATIONS IN DRUG TESTING While advancements

More information

Read the Questions Carefully

Read the Questions Carefully PHT. 463- (Quality Control of Pharmaceutical Dosage Forms) Midterm Exam I Dr. Ibrahim A. Alsarra s Section Part I Read the Questions Carefully TRUE OR FALSE: Indicate whether the statement is true or false

More information

SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS S7A

SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS S7A INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS

More information

ICH guideline S9 on nonclinical evaluation for anticancer pharmaceuticals

ICH guideline S9 on nonclinical evaluation for anticancer pharmaceuticals May 2010 EMA/CHMP/ICH/646107/2008 ICH guideline S9 on nonclinical evaluation for anticancer pharmaceuticals Step 5 Transmission to CHMP December 2008 Adoption by CHMP for release for consultation December

More information

LABORATORY INVESTIGATION OF SUSPECTED POISONING POISONS, PILLS & POTIONS

LABORATORY INVESTIGATION OF SUSPECTED POISONING POISONS, PILLS & POTIONS LABORATORY INVESTIGATION OF SUSPECTED POISONING POISONS, PILLS & POTIONS Dr Robin Braithwaite Director Regional Laboratory for Toxicology City Hospital, Birmingham (www.toxlab.co.uk) WHAT IS A POISON?

More information

Alterações empresariais sustentadas pelo conceito de engenharia do Produto Patrício Soares da Silva, MD, PhD

Alterações empresariais sustentadas pelo conceito de engenharia do Produto Patrício Soares da Silva, MD, PhD Alterações empresariais sustentadas pelo conceito de engenharia do Produto Patrício Soares da Silva, MD, PhD 1 Summary Hypothesis Generation Candidate Development Commercialization Target Identification

More information

Goals & Objectives. Drug Development & the FDA Pharmacy 309. Outline. An History of Disasters. Be able to describe

Goals & Objectives. Drug Development & the FDA Pharmacy 309. Outline. An History of Disasters. Be able to describe Drug Development & the FDA Pharmacy 309 Tom Hazlet, Pharm.D., Dr.P.H. 616-2732 thazlet@u... Goals & Objectives Be able to describe the major regulatory events in the drug development process the concepts

More information

Presented at: Jefferies 2015 Global Healthcare Conference

Presented at: Jefferies 2015 Global Healthcare Conference Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution

More information

Discovery safety assessment of drug projects can be considered in two broad areas: target-related safety and chemical related safety.

Discovery safety assessment of drug projects can be considered in two broad areas: target-related safety and chemical related safety. Toxicology Skills for Drug Discovery Why is Toxicology in Drug Discovery important? The development of novel pharmaceuticals requires non-clinical safety studies to be performed on candidate drugs. Such

More information

Apply with Resume to: www.rjrt.com Submenu Path Company/Careers/Current Openings/Job Type: Science

Apply with Resume to: www.rjrt.com Submenu Path Company/Careers/Current Openings/Job Type: Science Position: Biostatistician Required Experience: At least 5 years This position is responsible for providing broad statistical support in general and biostatistical support specifically, including study

More information

CTC Technology Readiness Levels

CTC Technology Readiness Levels CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.

More information

Expectations for Data to Support Clinical Trial Drugs

Expectations for Data to Support Clinical Trial Drugs Expectations for Data to Support Clinical Trial Drugs Presentation to: APEC Advanced Workshop on Review of Drug Development in Clinical Trials Bangkok Thailand Feb 2-6 2009 Willem Stevens Ph.D., Chief

More information

LGD 6972: Glucagon Receptor Antagonist

LGD 6972: Glucagon Receptor Antagonist LGD 6972: Glucagon Receptor Antagonist Highly Potent, Orally Bioavailable, Small Molecule Glucagon Receptor Antagonist for the Treatment of Type 2 Diabetes Overview Diabetes is one of the largest and fastest

More information

THE ASEAN COMMON TECHNICAL DOSSIER (ACTD) FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE PART III: NONCLINICAL DOCUMENT

THE ASEAN COMMON TECHNICAL DOSSIER (ACTD) FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE PART III: NONCLINICAL DOCUMENT THE ASEAN COMMON TECHNICAL DOSSIER (ACTD) FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE PART III: NONCLINICAL DOCUMENT PREAMBLE THE ASEAN COMMON TECHNICAL DOSSIER (ACTD) FOR THE REGISTRATION OF

More information

Medical Device Solutions. Battelle. Applied Research Device Development Clinical Research Sustaining Engineering

Medical Device Solutions. Battelle. Applied Research Device Development Clinical Research Sustaining Engineering Medical Device Solutions Battelle Applied Research Device Development Clinical Research Sustaining Engineering 0 2 Overview Applied Research Device Development Clinical Research Sustaining Engineering

More information

_Regulatory & Quality Compliance Graduate Certificate Program

_Regulatory & Quality Compliance Graduate Certificate Program _Regulatory & Quality Compliance Graduate Certificate Program An Important Three Course Program Presented by Purdue University, West Lafayette, IN Instructors: S. Byrn, M. Schmidt, and T. Wilson With emphasis

More information

Selvita Integrated drug discovery collaborations

Selvita Integrated drug discovery collaborations Selvita Integrated drug discovery collaborations Magdalena Żabka Selvita overview Origins Polish biotechnology research company headquartered in Krakow Mission Resources We deliver comprehensive solutions

More information

Introduction to Enteris BioPharma

Introduction to Enteris BioPharma Introduction to Enteris BioPharma Enteris BioPharma Intelligent Solutions for Oral Drug Delivery Privately held, New Jersey based biotech company Owned solely by Victory Park Capital, a large Chicago based

More information

THE BIOTECH & PHARMACEUTICAL INDUSTRY

THE BIOTECH & PHARMACEUTICAL INDUSTRY THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP) NOTE FOR GUIDANCE ON PROCESS VALIDATION

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP) NOTE FOR GUIDANCE ON PROCESS VALIDATION The European Agency for the Evaluation of Medicinal Products London, 1 March 2001 CPMP/QWP/848/96 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)

More information

Career opportunities for Ph.D. s in the pharmaceutical industry. Martin C. Michel, MD, MAE, FBPharmacolS

Career opportunities for Ph.D. s in the pharmaceutical industry. Martin C. Michel, MD, MAE, FBPharmacolS Career opportunities for Ph.D. s in the pharmaceutical industry Martin C. Michel, MD, MAE, FBPharmacolS Disclaimer This presentation is intended to inform about career opportunities in the pharmaceutical

More information

The Clinical Trials Process an educated patient s guide

The Clinical Trials Process an educated patient s guide The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-

More information

Host cell Protein Clearance and Detection: Critical issues for Biopharmaceutical development

Host cell Protein Clearance and Detection: Critical issues for Biopharmaceutical development Host cell Protein Clearance and Detection: Critical issues for Biopharmaceutical development Protein Quantification workshop, Waters: 13 th November 2012 Vincent Monchois, R&D and Pilot Services Manager,

More information

Physiologic Monitoring Systems for Life Science Research. Discover the possibilities with DSI.

Physiologic Monitoring Systems for Life Science Research. Discover the possibilities with DSI. Physiologic Monitoring Systems for Life Science Research Discover the possibilities with DSI. Flexible Solutions for Research CARDIOVASCULAR arterial and left ventricular pressures, ECG, activity, pressure

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products Center for

More information

ASMS Regulated Bioanalysis Interest Group (RBIG) Workshop. Antibody-Drug Conjugates (ADC) A Complex Problem in Regulated Bioanalysis.

ASMS Regulated Bioanalysis Interest Group (RBIG) Workshop. Antibody-Drug Conjugates (ADC) A Complex Problem in Regulated Bioanalysis. ASMS Regulated Bioanalysis Interest Group (RBIG) Workshop Antibody-Drug Conjugates (ADC) A Complex Problem in Regulated Bioanalysis June 17, 2014 Presiding: Dr. Keyang Xu (Genentech) and Dr. Fabio Garofolo

More information

September 19, 1984 FOOD PRODUCTION AND DIRECTION GÉNÉRALE, SECTION INSPECTION BRANCH PRODUCTION ET INSPECTION PESTICIDES DES ALIMENTS TRADE MEMORANDUM

September 19, 1984 FOOD PRODUCTION AND DIRECTION GÉNÉRALE, SECTION INSPECTION BRANCH PRODUCTION ET INSPECTION PESTICIDES DES ALIMENTS TRADE MEMORANDUM Agriculture Canada September 19, 1984 T-1-245 FOOD PRODUCTION AND DIRECTION GÉNÉRALE, SECTION INSPECTION BRANCH PRODUCTION ET INSPECTION PESTICIDES DES ALIMENTS TRADE MEMORANDUM RE: Guidelines for Developing

More information

FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN

FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN General Pantarhei Bioscience B.V. is an emerging specialty pharmaceutical company with a creative approach towards drug development. The Company

More information

PharmaceuticalDevelopment

PharmaceuticalDevelopment PharmaceuticalDevelopment Activities & Timelines Agenda Factors driving development Types of product Timelines for development Factors affecting length of development Regulation of Pharma environment Cost

More information

Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance

Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance by Tom Savage, NSF International Since 2008, when patient deaths were first linked to

More information

The Commercialization of Technology Concepts into Medical Products

The Commercialization of Technology Concepts into Medical Products The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community

More information

MSc in Toxicology. Master Degree Programme

MSc in Toxicology. Master Degree Programme Master Degree Programme MSc in Toxicology Department of Pharmaceutical Sciences, University of Basel Swiss Centre for Applied Human Toxicology (SCAHT) Master of Science in Toxicology University of Basel

More information

Micromyx. Micromyx. A Microbiology Services Company. Lab Services Research - Consulting -

Micromyx. Micromyx. A Microbiology Services Company. Lab Services Research - Consulting - A Microbiology Services Company Lab Services Research - Consulting - Regulatory Company description is a microbiology services company specializing in antiinfective discovery and development for the pharmaceutical,

More information

Scientific matters : What is human tissue?

Scientific matters : What is human tissue? Chapter 3 Scientific matters : What is human tissue? Introduction 3.1 In this chapter, we explain what we mean by human tissue. We start with a brief, general account of biological structures and their

More information

Recommended Dose Volumes for Common Laboratory Animals IQ 3Rs Leadership Group - Contract Research Organization Working Group

Recommended Dose Volumes for Common Laboratory Animals IQ 3Rs Leadership Group - Contract Research Organization Working Group NOTE: This document includes dose volume guidelines that have been researched and published as well as standards that have gained acceptance through empirical use across multiple members of the IQ 3Rs

More information

Introduction to pharmaceutical technology

Introduction to pharmaceutical technology Introduction to pharmaceutical technology Marie Wahlgren Chapter 1 What is the topics of today Introduction to the course Introduction to the project assignment How to choose a new drug formulation 1 Contacts

More information

Master of Applied Clinical and Preclinical Research Curriculum and Course Descriptions

Master of Applied Clinical and Preclinical Research Curriculum and Course Descriptions Program Description and Curriculum: For more information, please visit: www.macpr.osu.edu The (MACPR) program prepares graduates to excel as effective administrators, regulatory compliance specialists,

More information

Nuevas tecnologías basadas en biomarcadores para oncología

Nuevas tecnologías basadas en biomarcadores para oncología Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS

More information

Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements

Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements Pharmaceutical Sciences Applied sciences that underlie the practice of pharmacy the development, manufacture,

More information

Postmarket Surveillance -Adverse Event Reporting in the Office of Generic Drugs

Postmarket Surveillance -Adverse Event Reporting in the Office of Generic Drugs Postmarket Surveillance -Adverse Event Reporting in the Office of Generic Drugs Integration Communication Collaboration John R Peters, MD Director, Division of Clinical Review Office of Generic Drugs 1

More information

SIPBS Portfolio. 2012-13 Entry

SIPBS Portfolio. 2012-13 Entry SIPBS Portfolio 2012-13 Entry MSc Programmes Existing: MSc Pharmaceutical Analysis MSc Analysis of Medicines (distance learning) MSc Clinical Pharmacy New Programmes just launched for Sept 2012 entry:

More information

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to C 5 chemical development contract research custom synthesis cgmp API manufacturing commercial production Welcome to ChemCon Company profile Company profile ChemCon offers outstanding chemical services

More information

Overview of Phase 1 Oncology Trials of Biologic Therapeutics

Overview of Phase 1 Oncology Trials of Biologic Therapeutics Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of

More information

The FDA/CDER Chemical Informatics Program

The FDA/CDER Chemical Informatics Program The FDA/CDER Chemical Informatics Program Naomi Kruhlak, PhD Lead, Chemical Informatics Program Division of Applied Regulatory Science Office of Clinical Pharmacology Office of Translational Sciences FDA

More information

FDA STAFF MANUAL GUIDES, VOLUME I - ORGANIZATIONS AND FUNCTIONS FOOD AND DRUG ADMINISTRATION OFFICE OF GLOBAL AND REGULATORY OPERATIONS AND POLICY

FDA STAFF MANUAL GUIDES, VOLUME I - ORGANIZATIONS AND FUNCTIONS FOOD AND DRUG ADMINISTRATION OFFICE OF GLOBAL AND REGULATORY OPERATIONS AND POLICY SMG 1312.4 FDA STAFF MANUAL GUIDES, VOLUME I - ORGANIZATIONS AND FUNCTIONS FOOD AND DRUG ADMINISTRATION OFFICE OF GLOBAL AND REGULATORY OPERATIONS AND POLICY OFFICE OF REGULATORY AFFAIRS OFFICE OF OPERATIONS

More information

Pre-clinical DMPK and relevance to the clinic

Pre-clinical DMPK and relevance to the clinic Pre-clinical DMPK and relevance to the clinic Richard Weaver Ph.D Managing Director and Founder of XenoGesis limited BioCity Nottingham Pennyfoot Street Nottingham, UK NG1 1GF richard.weaver@xenogesis.com

More information

New Drug Application (NDA) Checklist

New Drug Application (NDA) Checklist New Drug Application (NDA) Checklist New Drug Applications (NDA) are very complex and detailed. It is difficult to know whether a company has included all of the information that is required by the applicable

More information

Program of Study: Bachelor of Science in Athletic Training

Program of Study: Bachelor of Science in Athletic Training Program of Study: Bachelor of Science Training Program Description Athletic training, as defined by the National Athletic Trainer s Association, is practiced by athletic trainers, health care professionals

More information

DEXAMETHASONE 0.5 MG TABLETS PL 17507/0052 TABLE OF CONTENTS

DEXAMETHASONE 0.5 MG TABLETS PL 17507/0052 TABLE OF CONTENTS DEXAMETHASONE 0.5 MG TABLETS PL 17507/0052 TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Steps taken after authorisation summary Page 12 Summary of

More information

Pharmaceutical Sciences

Pharmaceutical Sciences Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aapspharmaceutica.com/students How do I know if a career in the pharmaceutical sciences

More information

Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia

Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia Medicines for Neglected Diseases Workshop Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia September 11, 2010 Poverty, Many People Poor health conditions High Morbidity

More information

Post-Approval Change Management: Challenges and Opportunities An FDA Perspective

Post-Approval Change Management: Challenges and Opportunities An FDA Perspective CMC Workshop From Drug Development to Global Supply to Patients April 15-17, 2013, Washington, DC Post-Approval Change Management: Challenges and Opportunities An FDA Perspective Christine M. V. Moore,

More information

What ADME tests should be conducted for preclinical studies? Hong Wan

What ADME tests should be conducted for preclinical studies? Hong Wan ADMET & DMPK 1(3) (2013) 19 28; doi: 10.5599/admet.1.3.9 Open Access : ISSN : 1848 7718 Perspective What ADME tests should be conducted for preclinical studies? Hong Wan Shanghai Hengrui Pharmaceutical

More information

Plasma Drug Concentration Time Profile Plotting Data

Plasma Drug Concentration Time Profile Plotting Data UNIT 2 PHARMACOKINETICS-BASIC CONSIDERATIONS Plasma Drug Concentration Time Profile Plotting Data S. SANGEETHA., M.PHARM., (Ph.d) Department of Pharmaceutics SRM College of Pharmacy SRM University INTRODUCTION

More information

The Art of Auditing Bioanalytical Laboratories

The Art of Auditing Bioanalytical Laboratories Sponsor Audits of Bioanalytical Laboratories One of the critical tasks for a Good Laboratory Practices (GLP) nonclinical laboratory study or Clinical Trial team is choosing a bioanalytical laboratory vendor

More information